Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug

Thx Pharma SA

14/06/2023 06:56

June 14 (Reuters) - Theranexus SA  ALTHX.PA :
    * ENCOURAGING PRELIMINARY 6-MONTH RESULTS IN THE PHASE I/II
TRIAL
OF BATTEN-1 IN BATTEN DISEASE (CLN3)
    * REDUCTION OF NEUROFILAMENTS, A BIOMARKER OF NEURONAL
DEATH,
AFTER 6 MONTHS OF TREATMENT
    * STABILIZATION OF MOTOR SYMPTOMS FOR TREATED PATIENTS IN
COMPARISON TO DECLINE EXPECTED WITH NATURAL DISEASE COURSE
    * THESE PRELIMINARY RESULTS SUGGEST AN EFFECT OF BATTEN-1 ON
NEURONAL DEATH AND INITIAL SIGNS OF CLINICAL EFFICACY

Source text for Eikon:  ID:nACT80416 
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))